Terms: = Prostate cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Clinical Outcome
3 results:
1. Immune Checkpoints, Inhibitors and Radionuclides in prostate cancer: Promising Combinatorial Therapy Approach.
Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
[TBL] [Abstract] [Full Text] [Related]
2. B7-H4 is a potential prognostic biomarker of prostate cancer.
Li H; Piao L; Liu S; Cui Y; Xuan Y
Exp Mol Pathol; 2020 Jun; 114():104406. PubMed ID: 32088189
[TBL] [Abstract] [Full Text] [Related]
3. Global histone modification patterns predict risk of prostate cancer recurrence.
Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
[TBL] [Abstract] [Full Text] [Related]
